Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
Effective Treatment and Management of lymphoma requires a coordinated approach that blends accurate diagnosis, stage‑specific therapy, and ongoing supportive care. This page is designed for patients, families, and referring physicians seeking a clear overview of modern lymphoma care pathways, especially those considering treatment in an internationally accredited center.
Lymphoma represents a diverse group of blood cancers, affecting millions worldwide each year. According to recent global estimates, more than 600,000 new cases are diagnosed annually, and advances in targeted therapies have improved five‑year survival rates to over 70% for many subtypes. At Liv Hospital, our multidisciplinary team tailors each treatment and management plan to the individual’s disease biology, overall health, and personal preferences.
In the sections that follow, you will find detailed explanations of staging, chemotherapy, targeted and immunotherapy, radiation, stem‑cell transplantation, and the comprehensive supportive services that accompany every therapeutic decision. Whether you are exploring options for the first time or reviewing follow‑up strategies, this guide provides the essential information you need to make informed choices.
Accurate staging forms the backbone of effective treatment and management because it determines the disease’s extent and guides therapeutic intensity. Lymphomas are broadly classified into Hodgkin lymphoma (HL) and non‑Hodgkin lymphoma (NHL), each with distinct patterns of spread and prognostic factors.
Staging incorporates imaging (CT, PET‑CT), bone‑marrow biopsy, and laboratory studies. The result is a stage I–IV classification that reflects the number and location of involved lymph node regions and any extranodal disease.
Understanding these distinctions enables clinicians at Liv Hospital to construct a personalized treatment and management roadmap that maximizes efficacy while minimizing unnecessary toxicity.
Chemotherapy remains a cornerstone of lymphoma treatment and management, delivering systemic control of malignant cells. Regimens are selected based on lymphoma subtype, stage, patient age, and comorbidities.
Response rates vary, with R‑CHOP achieving complete remission in 60‑80 % of patients with DLBCL, while ABVD yields cure rates exceeding 80 % in early‑stage Hodgkin lymphoma.
At Liv Hospital, chemotherapy is administered in state‑of‑the‑art infusion suites with real‑time monitoring, and supportive medications such as anti‑emetics and growth factors are routinely incorporated to improve tolerance.
Advances in molecular biology have introduced targeted agents and immunotherapies that complement or replace traditional chemotherapy, offering a more precise treatment and management approach.
Liv Hospital’s oncology department participates in international clinical trials, granting patients access to these cutting‑edge therapies under rigorous safety protocols.
Radiation therapy (RT) serves both curative and consolidative roles within comprehensive lymphoma treatment and management, particularly for early‑stage disease or residual masses after systemic therapy.
Typical dosing schedules range from 20 Gy in 10 fractions for low‑risk Hodgkin lymphoma to 30‑36 Gy for bulky disease. Consolidation RT after chemotherapy improves local control, especially in mediastinal involvement.
Our radiation oncology team employs daily imaging and adaptive planning to minimize exposure to the heart, lungs, and thyroid, aligning with international safety standards.
For patients with high‑risk or relapsed lymphoma, stem‑cell transplantation (SCT) offers a potentially curative treatment and management pathway. Two main types are utilized:
Emerging modalities such as bispecific T‑cell engagers (e.g., mosunetuzumab) and next‑generation CAR‑T constructs are under investigation, promising deeper responses with reduced toxicity.
Liv Hospital’s transplant unit follows JCI‑accredited protocols, offering both inpatient and outpatient transplantation pathways, with dedicated transplant coordinators to streamline logistics for international patients.
Successful lymphoma treatment and management extends beyond active therapy. Ongoing supportive care mitigates side effects, preserves quality of life, and detects early relapse.
After completion of therapy, patients enter a structured follow‑up schedule:
Liv Hospital provides a dedicated survivorship clinic where multidisciplinary experts review long‑term health, coordinate vaccinations, and tailor lifestyle recommendations to each survivor’s needs.
Liv Hospital combines JCI accreditation, cutting‑edge oncology technology, and a 360‑degree international patient service model. Our board‑certified hematologists, radiation oncologists, and transplant specialists collaborate within a single campus, ensuring seamless coordination of diagnosis, therapy, and after‑care. International patients benefit from personalized concierge assistance—including visa support, airport transfers, interpreter services, and comfortable accommodation options—allowing them to focus solely on recovery.
Ready to discuss your personalized lymphoma treatment and management plan? Contact Liv Hospital’s International Patient Services today to schedule a confidential consultation and explore how our expert team can guide you toward the best possible outcome.
Liv Hospital Vadistanbul
Prof. MD. Itır Şirinoğlu Demiriz
Hematology
Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan
Pediatric Hematology and Oncology
Liv Hospital Ankara
Assoc. Prof. MD. Ramazan Öcal
Hematology
Liv Hospital Ankara
Prof. MD. Meral Beksaç
Hematology
Liv Hospital Ankara
Prof. MD. Oral Nevruz
Hematology
Liv Hospital Gaziantep
Assoc. Prof. MD. Fadime Ersoy Dursun
Hematology
Spec. MD. Ceyda Aslan
Hematology
Spec. MD. Elmir İsrafilov
Hematology
Spec. MD. Minure Abışova Eliyeva
Hematology
Liv Hospital Ulus + Liv Hospital Bahçeşehir
Prof. MD. Mehmet Hilmi Doğu
Hematology
Send us all your questions or requests, and our expert team will assist you.
Lymphoma staging determines disease extent and guides treatment intensity. Ann Arbor staging, originally developed for Hodgkin lymphoma, classifies disease from stage I to IV based on the number and location of involved lymph node regions and extranodal sites. For aggressive non‑Hodgkin lymphoma, the International Prognostic Index (IPI) adds factors such as patient age, serum LDH level, performance status, disease stage, and number of extranodal sites to predict outcomes. Indolent NHL uses the Revised European Prognostic Index (R‑EPI), which incorporates similar clinical variables tailored to slower‑growing subtypes. Accurate staging combines imaging (CT, PET‑CT), bone‑marrow biopsy, and laboratory tests.
For classic Hodgkin lymphoma, the ABVD regimen (Adriamycin, Bleomycin, Vinblastine, Doxorubicin) is given every 28 days and yields cure rates above 80 % in early stages. In aggressive B‑cell NHL, especially diffuse large B‑cell lymphoma (DLBCL), R‑CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) is administered every 21 days, achieving complete remission in 60‑80 % of patients. Other regimens include CHOP for CD20‑negative NHL and Hyper‑CVAD for lymphoblastic lymphoma. Response rates, cycle length, and toxicity profiles differ, so treatment is individualized based on subtype, stage, age, and comorbidities.
Targeted agents like rituximab (anti‑CD20) and newer antibodies (obinutuzumab, brentuximab vedotin) directly attack lymphoma cells while sparing normal tissue, improving outcomes when combined with chemotherapy. Immunotherapies, including checkpoint inhibitors (nivolumab, pembrolizumab) and CAR‑T cell therapy (e.g., axicabtagene ciloleucel), harness the patient’s immune system to recognize and destroy malignant cells. CAR‑T cells are especially effective in relapsed/refractory large B‑cell lymphoma, offering durable remissions. These modalities often allow reduced chemotherapy intensity, lower systemic toxicity, and are frequently available through clinical trials at Liv Hospital.
In Hodgkin lymphoma, involved‑node radiation therapy (INRT) of 20 Gy in 10 fractions is commonly used after chemotherapy to consolidate remission, especially for mediastinal disease. For bulky non‑Hodgkin lymphoma, intensity‑modulated radiation therapy (IMRT) delivering 30‑36 Gy improves local control. Radiation techniques such as 3‑D conformal RT, IMRT, and image‑guided RT (IGRT) enable precise dose delivery while protecting surrounding organs like the heart, lungs, and thyroid. The decision to add radiation depends on disease stage, response to chemotherapy, and patient‑specific risk factors.
Autologous stem cell transplantation (ASCT) collects the patient’s hematopoietic stem cells, administers high‑dose conditioning (e.g., BEAM), and reinfuses the cells to restore marrow function. It is the standard salvage approach for chemosensitive relapsed diffuse large B‑cell lymphoma, offering 5‑year survival around 55 %. Allogeneic transplantation uses a matched donor’s stem cells, providing a graft‑versus‑lymphoma immune effect useful for refractory disease, but it carries risks of graft‑versus‑host disease and higher treatment‑related mortality, with 5‑year survival near 40 % in selected studies. Liv Hospital follows JCI‑accredited protocols for both, offering inpatient and outpatient pathways.
Supportive care at Liv Hospital is integrated throughout treatment. Anti‑emetic regimens are tailored to the emetogenic potential of each chemotherapy protocol, and growth‑factor agents like filgrastim reduce neutropenia duration. Prophylactic antivirals and antifungals are used when indicated. Patients receive individualized nutrition counseling and physiotherapy to maintain strength, as well as psychosocial counseling, spiritual care, and access to patient‑support groups. After therapy, a survivorship clinic monitors for late toxicities, secondary malignancies, and cardiovascular health, coordinating vaccinations and lifestyle recommendations for long‑term wellbeing.
BlogHematologyApr 08, 2026Did you know that blood disorders affect millions of people worldwide, causing a wide range of health issue...
BlogHematologyApr 07, 2026Every year, over 1.8 million people in the United States get cancer. Hematology oncology is key in fighting...
BlogHematologyApr 06, 2026Pulmonary hemorrhage is a serious condition where blood enters the lung tissue and airways suddenly or over...
BlogHematologyApr 03, 2026Vitamin B12 and folic acid are key nutrients. They help keep red blood cells healthy, support nerve functio...
BlogHematologyApr 03, 2026Vitamin B is key for our health, helping with energy and brain function. At LivHospital, we know how import...
BlogHematologyApr 03, 2026Vitamin B12 and folate (vitamin B9) are essential nutrients for our nerves and for making red blood cells. ...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 174 26 75